Biologics Market Research Reports & Industry Analysis
The biologics industry includes a wide range of therapeutic products derived from biological sources and is a fundamental part of modern healthcare. Biologics play a vital role in advancing treatments for various diseases and conditions. MarketResearch.com offers a comprehensive collection of biologics industry reports to provide valuable insights into the most recent market trends, challenges, and opportunities to watch.
Biologics Market Growth Forecasts
- Access detailed information about a variety of distinct market segments, such as recombinant proteins, vaccines, and more.
- Obtain biologics market sizing and growth projections to gain a clear understanding of market potential and outlook.
- Analyze leading players and competitor strategies to stay one step ahead in a competitive market.
The MarketResearch.com Advantage
MakretResearch.com has been a trailblazer in the field of market research for more than two decades and continues to serve many of the largest life science and biotech companies in the world. With MarketResearch.com’s reliable data-driven insights, you can make informed decisions to guide your business towards success. Choose MarketResearch.com and gain the edge today.
Biologics Industry Research & Market Reports
-
Surgical Meshes Global Market Opportunities And Strategies To 2034 Including: 1) By Product Type: Synthetic Surgical Meshes; Biosynthetic Surgical Meshes; Biologic Surgical Meshes; Hybrid Or Composite Surgical Meshes 2) By Nature: Absorbable Surgical Meshes; Non-Absorbable Surgical Meshes; Partially Absorbable Surgical Meshes 3) By Sales Channel: Direct Channel; In-Direct Channel 4) By Application: Hernia Repair; Traumatic Or Surgical Wounds; Abdominal Wall Reconstruction; Facial Surgery 5) By End-User: Hospitals; Ambulatory Surgical Centers; Clinics Covering: Medtronic plc; Boston Scientific Corporation; Johnson & Johnson Services Inc.; Becton, Dickinson and Company; Lepu Medical Technology (Beijing) Co. Ltd.
... it emerges from the COVID-19 shut down. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies. Understand how the market is being affected by ... Read More
-
Pharmaceutical Contract Packaging Market Report by Industry (Small Molecule, Biopharmaceutical, Vaccine), Type (Sterile, Non-sterile), Packaging (Plastic Bottles, Caps and Closures, Blister Packs, Prefilled Syringes, Parenteral Vials and Ampoules, and Others), and Region 2025-2033
... 2025-2033. The increasing outsourcing trends, rising demand for medications and medical devices, stringent regulatory compliance, product diversification and cost-effectiveness, significant technological advancements, and increasing environmental considerations are some of the major factors propelling the market. ... Read More
-
Fill Finish Manufacturing
... at a CAGR of 8.6% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$13.7 Billion by the end of the ... Read More
-
Orthobiologics
... 4.2% over the analysis period 2024-2030. Viscosupplementation, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in ... Read More
-
Synthetic Orthobiologics
... CAGR of 5.6% over the analysis period 2024-2030. Osteoarthritis & Degenerative Arthritis Application, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$456.2 Million by the end ... Read More
-
Ampoules Packaging
... CAGR of 6.2% over the analysis period 2024-2030. Glass Material, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$5.6 Billion by the end of the analysis ... Read More
-
Bioburden Testing
... CAGR of 11.3% over the analysis period 2024-2030. Bioburden Testing Consumables, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.5 Billion by the end of the ... Read More
-
Peptide Synthesis
... CAGR of 4.3% over the analysis period 2024-2030. Peptide Synthesis Reagent, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$161.7 Million by the end of the ... Read More
-
Virus Filtration Products
... at a CAGR of 12.4% over the analysis period 2024-2030. Virus Filtration Kits & Reagents, one of the segments analyzed in the report, is expected to record a 13.6% CAGR and reach US$7.8 Billion by ... Read More
-
Amniotic Products
... CAGR of 8.1% over the analysis period 2024-2030. Amniotic Membranes, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$1.2 Billion by the end of the analysis ... Read More
-
Agricultural Biologicals Testing
... at a CAGR of 8.8% over the analysis period 2024-2030. Biopesticides Testing, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$1.5 Billion by the end of ... Read More
-
Biologics Safety Testing
... at a CAGR of 11.8% over the analysis period 2024-2030. Biologics Safety Testing Services, one of the segments analyzed in the report, is expected to record a 12.1% CAGR and reach US$5.5 Billion by the ... Read More
-
Plasma Protein Therapeutics
... at a CAGR of 4.8% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$9.3 Billion by the end of the ... Read More
-
Inflammatory Bowel Disease Treatment Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033
... 2033. Increased disease prevalence, improvements in biologic medicines, increased awareness, better diagnostics, and rising healthcare spending on specialist treatments are all factors propelling the market for treatments for inflammatory bowel disease. The report Inflammatory Bowel ... Read More
-
Wound Care Biologics
... at a CAGR of 9.8% over the analysis period 2024-2030. Biologic Skin Substitutes, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$3.1 Billion by the end ... Read More
-
Biological Drugs
... CAGR of 9.1% over the analysis period 2024-2030. Therapeutic Protein, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$289.1 Billion by the end of the analysis ... Read More
-
Biologics
... 8.2% over the analysis period 2024-2030. Recombinant Therapeutic Proteins, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$271.3 Billion by the end of the analysis period. ... Read More
-
Biopharmaceutical Logistics
... CAGR of 4.8% over the analysis period 2024-2030. Cold Chain Logistics, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$37.9 Billion by the end of the ... Read More
-
Allografts
... 6.9% over the analysis period 2024-2030. Demineralized Bone Matrix (DBM), one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$488.4 Million by the end of the analysis ... Read More
-
Autoinjectors
... 15.9% over the analysis period 2024-2030. Rheumatoid Arthritis Therapy, one of the segments analyzed in the report, is expected to record a 15.8% CAGR and reach US$47.6 Billion by the end of the analysis period. ... Read More
-
Bioprocess Containers
... CAGR of 23.7% over the analysis period 2024-2030. 2D Bioprocess Containers, one of the segments analyzed in the report, is expected to record a 27.1% CAGR and reach US$22.3 Billion by the end of the ... Read More
-
Burn Care
... CAGR of 3.9% over the analysis period 2024-2030. Advanced Burn Care, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$1.5 Billion by the end of the ... Read More
-
Spine Biologics
... CAGR of 4.4% over the analysis period 2024-2030. Spinal Allografts, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$1.4 Billion by the end of the analysis ... Read More
-
Biopharmaceutical Fermentation Systems
... at a CAGR of 4.5% over the analysis period 2024-2030. Upstream Products, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$6.5 Billion by the end of ... Read More
-
Generic Injectables
... CAGR of 11.8% over the analysis period 2024-2030. Large Molecule Injectables, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$145.9 Billion by the end of the ... Read More
Research Assistance
